← All indications
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.
Drugs by status
Approved for this indication (2)
Phase 4 trials (3)
Phase 3 trials (1)
Phase 2 trials (6)
Phase 1 trials (3)
Organizations
Organization Involved with Phase 4 Indications (4)
Organization Involved with Phase 3 Indications (14)
- Roche
- Alexion
- GlaxoSmithKline
- Omeros Corporation
- Rigel Pharmaceuticals
- Medicines for Malaria Venture
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Universidad Autonoma de Nuevo Leon
- University of Copenhagen
- University of Toulouse
- Momenta Pharmaceuticals
- University of Paris
- Exeltis
- immunova
Organization Involved with Phase 2 Indications (38)
- Incyte
- Sanofi
- Alnylam Pharmaceuticals
- ChemoCentryx
- Hamilton Health Sciences Corporation
- Apellis Pharmaceuticals, Inc.
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- Helse Fonna
- University of Pennsylvania
- Rockefeller University
- Boston University
- Harvard University
- Emory University
- Johns Hopkins University
- McMaster University
- University of Milan
- University of Oslo
- University of Toronto
- University of Bordeaux
- Mayo Clinic
- University of California, San Francisco
- University of Cincinnati
- University of Turku
- University of Udine
- Annexon
- City of Hope National Medical Center
- Mario Negri Institute
- Vita-Salute University of Milano. Italy
- +8 more
Organization Involved with Phase 1 Indications (15)
- Syntimmune, Inc.
- Telethon Kids Institute
- University of Melbourne
- University of Tennessee
- Assiut University
- University of Auckland
- Nucleus Network Ltd
- University of Queensland
- Free University of Brussels
- National Health and Medical Research Council, Australia
- University of Wollongong
- The Peter Doherty Institute
- Griffith University
- Murdoch University
- Yeshiva University
Organization Involved with Other Experimental Indications (5)